MaaT Pharma Publishes its Half-Year 2026 Results and Provides a Business Update

Regulatory News:MaaT Pharma (EURONEXT:MAAT — the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced its half-year financial r…